Emerald Advisers LLC Sells 234 Shares of Eli Lilly and Company $LLY

Emerald Advisers LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 18.3% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,047 shares of the company’s stock after selling 234 shares during the period. Emerald Advisers LLC’s holdings in Eli Lilly and Company were worth $816,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at about $27,000. Blume Capital Management Inc. boosted its position in Eli Lilly and Company by 46.7% in the second quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after buying an additional 14 shares in the last quarter. IMG Wealth Management Inc. acquired a new position in Eli Lilly and Company in the second quarter valued at about $35,000. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company in the first quarter valued at about $40,000. Finally, TD Capital Management LLC boosted its position in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. UBS Group dropped their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. DZ Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. BMO Capital Markets increased their target price on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Finally, Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $938.61.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $810.78 on Thursday. The firm has a 50-day moving average of $775.02 and a 200-day moving average of $770.34. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a market cap of $767.37 billion, a PE ratio of 52.99, a P/E/G ratio of 1.22 and a beta of 0.47. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s payout ratio is 39.22%.

Insider Buying and Selling

In related news, Director Jamere Jackson purchased 200 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares of the company’s stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.